$CHNC China Infrastructure Construction Corp. (OTC
Post# of 26670
(Total Views: 71)
Posted On: 12/09/2019 11:53:56 AM
$CHNC China Infrastructure Construction Corp. (OTCPK: CHNC) is Pleased to Announce its Acquisition of Precision Research Institute, LLC (PRI)
HOUSTON, TX, Oct. 21, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – China Infrastructure Construction Corp. (OTCPK: CHNC) www.chnc-hdh.com is pleased to announce its acquisition of Precision Research Institute, LLC (PRI).
PRI is a Multi-Therapeutic, Dedicated Research Unit based in Houston, Texas. PRI brings multi-million-dollar contracts with the largest pharmaceutical companies in the world--like Abbvie, Samumed, Gilead, Intercept, Shire Pharmaceuticals, and more. President & CEO Elizabeth Hernandez says, “This acquisition of PRI, our second in the past year, now puts CHNC in the unique position of conducting its own clinical research trials. Which holds an important value the to the future of Medicine. CHNC is now in position to be the leader in the arena of Medical Clinical Trials. CHNC is in the process of becoming its very own Contract Research Organization (CRO) in the Industry. The looking forward to developing the future of Pharmaceutical, Biotechnology, and Pharmacovigilance Clinical Trials. PRI has Phase I, II, and III clinical trial capabilities--a rare feat. PRI’s facility is 4500 sq. ft. and currently has ongoing Phase II, III clinical trials, along with observational studies. Their fifteen active multi-million-dollar contracts is a great head start for CHNC. We look forward to expanding quickly!”
The acquisition, which has been approved by the board of directors, is subject to certain closing conditions, including OTC approval, approval by the stockholders of China Infrastructure Construction Corp. (CHNC), minimum cash balance of CHNC at closing, and other customary closing conditions.
About China Infrastructure Construction Corp. (OTCPK: CHNC)
Hippocrates Direct Healthcare, Inc. is a wholly owned subsidiary of CHNC, maintains a medical office, and also does clinical research for pharmaceutical companies. Hippocrates began with its membership-based model and now provides stem cell and clinical research services.
Hippocrates Direct Healthcare, Inc. is a wholly-owned subsidiary of China Infrastructure (OTCPK: CHNC). China Infrastructure's common stock trades on the OTC Markets under the ticker symbol "CHNC."
Safe Harbor Statement
The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "projects," "intends," and similar phrases. Forward-looking statements involve risks and uncertainties that could cause actual results to differ from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of geopolitical conditions, competition, changes in technology and methods of marketing, and various other factors beyond the company's control.
Hippocrates Direct Healthcare™ and the Hippocrates Direct Healthcare™ logo are all trademarks or registered trademarks of Hippocrates Direct Healthcare™, Inc.
CONTACTS:
Investors:
Hippocrates Direct Healthcare™, Inc.
Elizabeth@chnc-hdh.com
832-606-7500
HOUSTON, TX, Oct. 21, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – China Infrastructure Construction Corp. (OTCPK: CHNC) www.chnc-hdh.com is pleased to announce its acquisition of Precision Research Institute, LLC (PRI).
PRI is a Multi-Therapeutic, Dedicated Research Unit based in Houston, Texas. PRI brings multi-million-dollar contracts with the largest pharmaceutical companies in the world--like Abbvie, Samumed, Gilead, Intercept, Shire Pharmaceuticals, and more. President & CEO Elizabeth Hernandez says, “This acquisition of PRI, our second in the past year, now puts CHNC in the unique position of conducting its own clinical research trials. Which holds an important value the to the future of Medicine. CHNC is now in position to be the leader in the arena of Medical Clinical Trials. CHNC is in the process of becoming its very own Contract Research Organization (CRO) in the Industry. The looking forward to developing the future of Pharmaceutical, Biotechnology, and Pharmacovigilance Clinical Trials. PRI has Phase I, II, and III clinical trial capabilities--a rare feat. PRI’s facility is 4500 sq. ft. and currently has ongoing Phase II, III clinical trials, along with observational studies. Their fifteen active multi-million-dollar contracts is a great head start for CHNC. We look forward to expanding quickly!”
The acquisition, which has been approved by the board of directors, is subject to certain closing conditions, including OTC approval, approval by the stockholders of China Infrastructure Construction Corp. (CHNC), minimum cash balance of CHNC at closing, and other customary closing conditions.
About China Infrastructure Construction Corp. (OTCPK: CHNC)
Hippocrates Direct Healthcare, Inc. is a wholly owned subsidiary of CHNC, maintains a medical office, and also does clinical research for pharmaceutical companies. Hippocrates began with its membership-based model and now provides stem cell and clinical research services.
Hippocrates Direct Healthcare, Inc. is a wholly-owned subsidiary of China Infrastructure (OTCPK: CHNC). China Infrastructure's common stock trades on the OTC Markets under the ticker symbol "CHNC."
Safe Harbor Statement
The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "projects," "intends," and similar phrases. Forward-looking statements involve risks and uncertainties that could cause actual results to differ from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of geopolitical conditions, competition, changes in technology and methods of marketing, and various other factors beyond the company's control.
Hippocrates Direct Healthcare™ and the Hippocrates Direct Healthcare™ logo are all trademarks or registered trademarks of Hippocrates Direct Healthcare™, Inc.
CONTACTS:
Investors:
Hippocrates Direct Healthcare™, Inc.
Elizabeth@chnc-hdh.com
832-606-7500
(0)
(0)Scroll down for more posts ▼